Therapies for rare diseases encouraged despite expense
It is no secret that pharmaceutical and biotech companies are beginning to invest heavily in the rare disease space. One of the attractions is that orphan drugs, developed for the treatment of rare and ultra-rare disorders, tend to be very expensive, where single patient costs can reach $350,000 and above per year.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter